NOVEL THERAPEUTIC STRATEGIES
https://doi.org/10.18705/1607-419X-2014-20-1-27-33
Abstract
The article reviews the main changes in therapeutic approaches for hypertension management according to the European guidelines 2013, in particular, special conditions are discussed, including patients with cardiovascular diseases, diabetes mellitus, chronic kidney disease, elderly population? the advantages of less aggressive approach are discussed.
About the Authors
Y. V. Kotovskaya
Russian People’s Friendship University, Moscow
Russian Federation
Corresponding author: Clinical Hospital № 64, the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University, 61 Vavilov st., Moscow, Russia, 117292., E-mail: kotovskaya@bk.ru (Julia V. Kotovskaya, MD, PhD, Professor at the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University).
Russian Federation
Corresponding author: Clinical Hospital № 64, the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University, 61 Vavilov st., Moscow, Russia, 117292., E-mail: kotovskaya@bk.ru (Julia V. Kotovskaya, MD, PhD, Professor at the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University).
O. V. Kravtsova
Russian People’s Friendship University, Moscow
Russian Federation
Russian Federation
E. A. Pavlova
Russian People’s Friendship University, Moscow
Russian Federation
Russian Federation
References
1. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1105–1187.
2. Mancia G., Fagard R., Narkiewicz R., Redon J., Zanchetti A., Bohm M et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension // J. Hypertens. — 2013. — Vol. 31, № 7. — P. 1281–1357.
3. Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes // Kidney Int. — 2002. — Vol. 61, № 3. — P. 1086–1097.
4. PATS Collaborating Group. Poststroke antihypertensive treatment study. A preliminary result // Chin. Med. J. (Engl). — 1995. — Vol. 108, № 9. — P. 710–717.
5. Arima H., Chalmers J., Woodward M., Anderson C., Rodgers A., Davis S. et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial // J. Hypertens. — 2006. — Vol. 24, № 6. — P. 1201–1208.
6. Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re-appraisal // J. Hypertens. — 2009. — Vol. 27, № 5. — P. 923–934.
7. Sipahi I., Swamiinathan A., Natesan V., Debanne S.M., Simon D.I., Fang J.C. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials // Stroke. — 2012. — Vol. 43, № 2. — P. 432–440.
8. Julius S., Nesbitt S.D., Egan B.M., Weber M.A., Michelson E.L., Karioti N. et al. Feasibility of treating prehypertension with an angiotensin receptor blocker // N. Engl. J. Med. 2006. — Vol. 354, № 16. — P. 1685–1697.
9. DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial // Diabetes Care. — 2008. — Vol. 31, № 8. — P. 1007–1014.
10. The NAVIGATOR study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events // N. Eng. J. Med. — 2010. — Vol. 362, № 16. — P. 1477–1490.
11. Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J. et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. — 2011. — Vol. 364, № 10. — P. 907–917.
12. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial // Lancet. — 2008. — Vol. 372, № 9638. — P. 547–553.
13. Bakris G.L., Seraidis P.A., Weir M.R., Dalhof B., Pitt B., Jamerson K. et al., ACCOMPLISH Trial Investigators. Renal outcomes with different ixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOM-PLISH): a prespeciied secondary analysis of randomised controlled trial // Lancet. — 2010. — Vol. 375, № 9721. — P. 1173–1181.
14. Costanzo P., Perrone-Filardi P., Vassallo E., Paolillo S., Cesarano P., Brevetti G., Chiariello M. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials // J. Am. Coll. Cardiol. 2010. — Vol. 56, № 24. — P. 2006–2020.
15. Goldberger Z.D., Valle J.A., Dandekar V.K., Chan P.S., Ko D.T., Nallamothu B.K. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis // Am. Heart. J. — 2010. — Vol. 160, № 4. — P. 701–714.
Review
For citations:
Kotovskaya Y.V., Kravtsova O.V., Pavlova E.A. NOVEL THERAPEUTIC STRATEGIES. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2014;20(1):27-33. (In Russ.) https://doi.org/10.18705/1607-419X-2014-20-1-27-33
Views:
902
Email this article 